Allogeneic ABCB5+ Mesenchymal Stem Cells for Treatment-Refractory Chronic Venous Ulcers: A Phase I/IIa Clinical Trial

• Main Authors: Andreas Kerstan (Author), Kathrin Dieter (Author), Elke Niebergall-Roth (Author), Ann-Kathrin Dachtler (Author), Korinna Kraft (Author), Markus Stücker (Author), Georg Daeschlein (Author), Michael Jünger (Author), Tobias Görge (Author), Ulrich Meyer-Pannwitt (Author), Cornelia Erfurt-Berge (Author), Charlotte von Engelhardt (Author), Andreas Klare (Author), Christiane Pfeiffer (Author), Jasmina Esterlechner (Author), Hannes M. Schröder (Author), Martin Gasser (Author), Ana M. Waaga-Gasser (Author), Matthias Goebeler (Author), Seda Ballikaya (Author), Samar Sadeghi (Author), George F. Murphy (Author), Dennis P. Orgill (Author), Natasha Y. Frank (Author), Christoph Ganss (Author), Karin Scharffetter-Kochanek (Author), Markus H. Frank (Author), Mark A. Kluth (Author)
• Format: Book
• Published: Elsevier, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A significant number of chronic venous ulcers (CVUs) fail to heal despite guideline-conform standards of care. Skin-derived ABCB5+ mesenchymal stem cells can dampen the sustained IL-1β‒driven inflammation present in chronic wounds. On the basis of their wound healing‒facilitating effects in a mouse...